Xeltis
Develops artificial blood vessels and heart valves designed to be replaced over time by a patient’s own tissue.
Overview
Xeltis is a Dutch-US MedTech company developing artificial vessels and valves intended for implantation and eventual replacement by the patient’s own tissue. Its products address cardiovascular repair markets where clinicians need alternatives for vessel and valve replacement. The company’s differentiation is its tissue-restoration approach, positioning the implant as a scaffold rather than a permanent device. Xeltis raised about €21 million in an undisclosed 2026 round to advance its artificial vessels and valves.
Funding History
Dutch-US MedTech Xeltis raises €20.5 million to advance artificial vessels and valves replaced by patients’ own tissue
Frequently Asked Questions
- How much funding does AI Funding track for Xeltis?
- AI Funding tracks €21M for Xeltis across 1 funding round in this database.
- What does Xeltis do?
- Xeltis is a Dutch-US MedTech company developing artificial vessels and valves intended for implantation and eventual replacement by the patient’s own tissue. Its products address cardiovascular repair markets where clinicians need alternatives for vessel and valve replacement. The company’s differentiation is its tissue-restoration approach, positioning the implant as a scaffold rather than a permanent device. Xeltis raised about €21 million in an undisclosed 2026 round to advance its artificial vessels and valves.
- Where is Xeltis headquartered?
- Xeltis is headquartered in Eindhoven, Netherlands.
Related Insights
Compare the leading AI-focused VC firms: Andreessen Horowitz, Sequoia Capital, Thrive Capital, and 7 more. Analysis of 150+ AI deals, investment strategies, sector focus, and portfolio performance.
Track 395+ AI funding rounds—investors, valuations, and deal sizes from pre-seed to IPO. Updated daily so you never miss a round.
An in-depth look at how AI-focused venture capital operates — from fund structure and deal sourcing to due diligence, portfolio management, and exit strategies in the AI era.